| Biogen Inc. | 20,469.00 / -1.20% |
| Date/Time | 04/16 / 22:12 |
| Chg. / Chg.(%) | -249.00 / -1.20% |
| Bid | 20,350.00 / 5 |
| Ask | 20,663.00 / 1 |
| Open | 20,443.00 |
| Previous Close | 20,718.00 |
| High | 20,717.00 |
| Low | 20,278.00 |
| Volume [RUB] | 3,155,099.00 |
| Volume [Units] | 159 |
| Price fixings | 410 |
| ISIN | US09062X1037 |
| Security | BIIB-RM/ID |
| Exchange | Moscow |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Lang & Schwa.. | 225.800 |  |
|
| NASDAQ | 270.3100 | |
1,014,812 |
| IEX | 270.25 | |
46,002 |
| Cboe US | 270.26 | |
38,822 |
| Xetra | 226.75 | |
1,092 |
| London Inter.. | 271.02 | |
579 |
| TradeGate | 225.700 | |
414 |
| Vienna Globa.. | 226.35 | |
213 |
| Moscow | 20,469.00 |  |
159 |
| Frankfurt | 224.2000 | |
96 |
| Stuttgart | 225.950 | |
43 |
| gettex | 226.250 | |
14 |
| Berlin | 225.60 | |
4 |
| München | 224.45 |  |
0 |
| Hamburg | 224.45 | |
0 |
| Düsseldorf | 226.00 | |
0 |
| Hannover | 224.45 | |
0 |
| Mexico | 5,412.83 | |
18,390 |
News
- New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis
04/16/2021 / 13:30 - GlobeNewswire - Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
04/15/2021 / 22:30 - GlobeNewswire - Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2020
04/14/2021 / 22:40 - GlobeNewswire - Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021
04/14/2021 / 22:06 - GlobeNewswire - Yumanity Therapeutics Appoints Neuroscience Drug Development Veteran, Ajay Verma, M.D., Ph.D., Executive Vice President, Head of Research & Development
04/13/2021 / 14:00 - GlobeNewswire
Real-time